Fracture risk assessment by the FRAX model
暂无分享,去创建一个
W. Leslie | L. Vandenput | J. Kanis | E. McCloskey | N. Harvey | E. Liu | H. Johansson | M. Lorentzon
[1] J. Kanis,et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines , 2021, Osteoporosis International.
[2] J. Kanis,et al. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study , 2021, Osteoporosis International.
[3] J. Kanis,et al. Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures , 2020, Osteoporosis International.
[4] J. Kanis,et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures , 2020, Osteoporosis International.
[5] P. Geusens,et al. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial , 2020, Osteoporosis International.
[6] T. Peters,et al. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study , 2020, Osteoporosis International.
[7] Jennifer E. Moore,et al. Agency for Healthcare Research and Quality , 2020, Definitions.
[8] J. Kanis,et al. A decade of FRAX: how has it changed the management of osteoporosis? , 2020, Aging Clinical and Experimental Research.
[9] H. E. van der Horst,et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis , 2019, Osteoporosis International.
[10] C. Cooper,et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.
[11] F. Rutters,et al. The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[12] J. Kanis,et al. Temporal changes in access to FRAX® in Thailand between 2010 and 2018 , 2019, Archives of Osteoporosis.
[13] J. Kanis,et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability , 2019, Archives of Osteoporosis.
[14] J. Kanis,et al. A brief history of FRAX , 2018, Archives of Osteoporosis.
[15] J. Kanis,et al. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[16] M. Phipps,et al. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.
[17] P. Geusens,et al. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[18] C. Cooper,et al. The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[19] C. Cooper,et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.
[20] P. Geusens,et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.
[21] M. Leshno,et al. Fracture Risk Assessment With FRAX Using Real-World Data in a Population-Based Cohort From Israel , 2018, American journal of epidemiology.
[22] J. Kanis,et al. FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.
[23] M. Bech,et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.
[24] A. Grauer,et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.
[25] J. Kanis,et al. The Effect of Abaloparatide‐SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] E. Skovlund,et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway , 2017, Osteoporosis International.
[27] Ran D Balicer,et al. External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study , 2017, British Medical Journal.
[28] J. Kanis,et al. FRAX Update. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[29] C. Cooper,et al. A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.
[30] J. Kanis,et al. Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[31] Jacques P. Brown,et al. A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] J. Kanis,et al. Intervention Thresholds and the Diagnosis of Osteoporosis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[33] J. Kanis,et al. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.
[34] J. Kanis,et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.
[35] C. Cooper,et al. FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.
[36] D. Mellström,et al. Is the Swedish FRAX model appropriate for Swedish immigrants? , 2015, Osteoporosis International.
[37] J. Kanis,et al. Adjusting Fracture Probability by Trabecular Bone Score , 2015, Calcified Tissue International.
[38] A. LaCroix,et al. Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts , 2014, Calcified Tissue International.
[39] J. Cauley,et al. Geographic and ethnic disparities in osteoporotic fractures , 2014, Nature Reviews Endocrinology.
[40] C. Cooper,et al. Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.
[41] E. M. Lewiecki,et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
[42] Naoto Endo,et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.
[43] S. Cummings,et al. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: The fracture intervention trial , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[44] J. Kanis,et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] J. Kanis,et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[46] Carol Coupland,et al. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.
[47] C. Cooper,et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.
[48] C. Cooper,et al. A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.
[49] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[50] S. Boonen,et al. Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[51] J. Kanis,et al. FRAX® with and without Bone Mineral Density , 2011, Calcified Tissue International.
[52] L. Lix,et al. Fracture risk assessment without bone density measurement in routine clinical practice , 2011, Osteoporosis International.
[53] W. Leslie,et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos , 2011, Osteoporosis International.
[54] J. Kanis,et al. Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement , 2011, Osteoporosis International.
[55] J. Kanis,et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.
[56] Eugene McCloskey,et al. Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[57] J. Kanis,et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.
[58] R. Chou,et al. Screening for Osteoporosis , 2010 .
[59] Carol Coupland,et al. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.
[60] J. Kanis,et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.
[61] C. Cooper,et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. , 2009, Maturitas.
[62] J. Kanis,et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.
[63] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[64] L. Melton,et al. A reference standard for the description of osteoporosis. , 2008, Bone.
[65] L. Melton,et al. Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.
[66] O. Johnell,et al. FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.
[67] G. Anderson,et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.
[68] N. D. Nguyen,et al. Development of a nomogram for individualizing hip fracture risk in men and women , 2007, Osteoporosis International.
[69] Jacques P. Brown,et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.
[71] O. Johnell,et al. Requirements for DXA for the management of osteoporosis in Europe , 2005, Osteoporosis International.
[72] O. Johnell,et al. Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.